Breaking News

Daiichi Licenses ArQule Cancer Compound

ARQ 092 will be studied to identify efficacy in targeting the AKT signaling pathway

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. have entered a license agreement under which Daiichi obtains exclusive rights for the development, manufacture and marketing of ARQ 092 on a worldwide basis. ARQ 092 is the first compound to result from the companies’ November 2008 research collaboration using AKIP (ArQule Kinase Inhibitor Platform) technology to generate selective and potent small molecule kinase inhibitors. ARQ 092 will be studied in cancer patients to identify its efficacy in targeti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters